ASSAD DARAWAL: Open Payments
NPI 1902877301 · INDIO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 46 payments from 18 companies in 2025. Trend: 2023 $853 · 2024 $1,128 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $330 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $122 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| GlaxoSmithKline, LLC. | 3 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Novo Nordisk Inc | 2 | $39 |
| Electromed, Inc. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $32 |
| PFIZER INC. | 1 | $30 |
Products named: AIRSUPRA, XIFAXAN, Kerendia, REXULTI, FARXIGA, TRELEGY ELLIPTA, ELIQUIS, Wegovy.
Industry payments across CA — which companies pay providers there.
